InvestorBrandNetwork Highlights PaxMedica Inc.’s (NASDAQ: PXMD) Video Release on Transformative ASD Study
In a significant development for the neurological disorder community, PaxMedica (NASDAQ: PXMD) has released an insightful video detailing the outcomes of its Phase 2 study on Autism Spectrum Disorder (“ASD”), initially published in the Annals of General Psychiatry. This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD. The study, a comprehensive 14-week randomized, double-blind, placebo-controlled trial, enrolled 52 boys aged 4–15 years with moderate to severe ASD. Focused on evaluating the efficacy and safety of…